• Julien Guinde, Romain Carron, Pascale Tomasini, Laurent Greillier, Jean Régis, and Fabrice Barlesi.
• Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, Public Hospital, Marseille, France. Electronic address: guindejulien@gmail.com.
• World Neurosurg. 2017 Nov 1; 107: 1047.e1-1047.e4.

IntroductionIn the context of bronchial cancers, the brain is one of the most frequent sites for metastases. Local treatments of these metastases have evolved and are often combined to obtain greater efficiency, while the main objective remains to reduce the symptoms. Radiosurgery is currently used as a primary option for patients harboring few numbers of small to middle-sized brain metastases. In nonsquamous non-small cell lung cancer (NSCLC), chemotherapy is often associated with bevacizumab. Our goal was to assess the safety of this early combination.Clinical Practice PointsSix patients with advanced nonsquamous NSCLC were treated with radiosurgery for the management of their brain metastases (n = 40), followed within <4 weeks by a treatment with bevacizumab. No systemic or cerebral adverse event of grade 3 (intratumoral or parenchymal hemorrhage) or unexpected toxicity secondary to bevacizumab has been indexed.ConclusionRadiosurgery may be safely combined with bevacizumab quite early on for patients with nonsquamous NSCLC with brain metastases.Copyright © 2017 Elsevier Inc. All rights reserved.

32 keywords...

hide…